Recently, various DTP cell markers have been reported to function in or mediate EGFR-TKI resistance in EGFR-mutated lung cancer, and these could, therefore, serve as novel therapeutic targets [15, 28, 29]. The gene discussed is EGFR; the disease is lung cancer.